SLC5A2 and chronic kidney disease: Use of an SGLT-2 inhibitor was associated with a lower incidence of cardiovascular death in patients with CKD, compared with placebo: RR 0.87 (95% CI 0.79–0.95; P = 0.003) (Fig. 1 and Table 3).